FOR IMMEDIATE RELEASE:
PrimeraDx Receives Issuance of Key Patent
Mansfield, MA — May 24, 2008 — PrimeraDx, Inc. today announced the issuance of a key patent further strengthening its position in multiplexed and quantitative nucleic acid analysis.
The patent, entitled “Quantitative Gene Expression Profiling” with inventors Vladimir Slepnev, Ph.D. and Elizabeth Garcia Ph.D., describes approaches to the measurement of target nucleic acids, e.g., DNAs or RNAs in a sample, both in single and in multiplex format.
“This patent is a significant addition to our portfolio describing our proprietary STAR technology. It will help enable our vision to build PrimeraDx into a world leader in personalized medicine through cost effective multi-genetic tests,” said Martin L. Verhoef, President and CEO of PrimeraDx.
PrimeraDx is dedicated to the emerging field of molecular diagnostics. The company is developing multiplexed, quantitative and cost effective assays using its proprietary STAR technology implemented on the ICEPlex instrument platform. STAR combines quantitative PCR with the ability to multiplex up to 60 targets in a single sample. The Company’s initial products are for infectious disease management. PrimeraDx plans to extend its focus into oncology to support cancer therapy management through diagnostic, prognostic, staging and therapeutic monitoring. The Company’s website is: www.primeradx.com .